Please ensure Javascript is enabled for purposes of website accessibility

Why Co-Diagnostics Stock Is Up 50% in May After Soaring 49% in April

By Beth McKenna – May 11, 2020 at 8:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This coronavirus testing company's stock has increased 19 times in 2020.

What happened

Shares of Co-Diagnostics (CODX 5.23%), which is primarily focused on healthcare diagnostics, has skyrocketed 50.5% in May, through Monday, the 11th. This follows its scorching performance last month, when it soared 48.8%, according to data from S&P Global Market Intelligence. In 2020, it's up just over 1,800% -- that's a 19-bagger.

By comparison, the S&P 500 index has returned just under 1% so far in May, and returned 12.8% in April. Last month's strong market performance should be placed in context: It followed a big coronavirus-driven sell-off in March, when the S&P 500 (including dividends) dropped 12.4%. In 2020, the broader market is down nearly 9%.

A gloved hand holding a vial of blood labeled "coronavirus" with "no" checked (instead of "yes")

Image source: Getty Images.

So what

April

Co-Diagnostics stock probably got a boost from the strength of the overall market last month. But the main reason for its robust April performance is investor enthusiasm over the sales potential of the company's Logix Smart test to detect SARS-CoV-2, the virus that causes COVID-19.

On April 16, shares shot up nearly 44% after the company announced that its coronavirus testing technology had been validated by OralDNA Labs for use on saliva samples. People find saliva testing a much more palatable (pardon the pun) way to be tested than by nasal swabbing. 

OralDNA Labs is certified under Clinical Laboratory Improvement Amendments (CLIA) under the Food and Drug Administration's Emergency Use Authorization (EUA) program. Co-Diagnostics' COVID-19 test is available at all such certified labs.

May

We can attribute Co-Diagnostics stock's strong performance so far in May to both a continuation of its momentum from April as well as some specific news.

Notably, on May 4, shares popped about 11% after the company announced two positive developments: Its Logix Smart COVID-19 test was approved for sale in Mexico, and the Saragene COVID-19 test, made by its CoSara joint venture, was given the green light to be sold in India. 

Now what

Co-Diagnostics isn't currently profitable. However, Wall Street expects the company to be profitable, at least on an adjusted basis, for full-year 2020.

In 2020, analysts are projecting the company will post adjusted earnings per share (EPS) of $0.01 on revenue of $14.7 million. Last year, Co-Diagnostics had a loss per share of $0.36 on sales of just $215,000. 

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
CODX
$3.02 (5.23%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.